Pharmaceutical company Biovitrum

Presenting Swedish Orphan Biovitrum

Biovitrum and Swedish Orphan have combined forming Swedish Orphan Biovitrum. The mission of the new company is to develop and make available orphan drugs and niche specialty pharmaceuticals for patients with rare diseases and with high unmet medical needs. Read the article about the merger.

A new website is not available yet and for the time being we kindly refer to our former home pages. Go to Swedish Orphan International website here.

Our products

Biovitrum is dedicated in helping people to a better life by developing new and innovative products to counter unmet medical needs

Presenting Swedish Orphan Biovitrum
Biovitrum and Swedish Orphan have combined forming Swedish Orphan Biovitrum. The mission of the new company is to develop and make available orphan drugs and niche specialty pharmaceuticals for patien

Biovitrum completes the acquisition of Swedish Orphan International
Biovitrum has today completed the previously announced acquisition of Swedish Orphan International. Read more about the deal here

Boy is playing Biovitrum and Biogen Idec Decide to Advance Hemophilia B Therapy into Registrational Trial

We develop rFIXFc for the treatment of hemophilia B, the goal being that patients will need less frequent prophylactic injections than with currently existing therapies. Read more ..